Comparison of the everolimus eluting XIENCE-V* stent with the paclitaxel eluting TAXUS* stent in all-comers: a randomized open label study.

Comparison of the everolimus eluting XIENCE-V* stent with the paclitaxel eluting TAXUS* stent in all-comers: a randomized open label study. - MCRZ-COMPARE

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35195

Enrollment

1600

Registered

2007-02-01

Start date

2007-02-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

outcome PCI treatment

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All patients referred for PCI according to dutch and european guidelines Age between 18-85 years

Exclusion criteria

Exclusion criteria: 1 Expected non-adherence to dual antiplatelet therapy for 1 year (e.g: known allergy to ASA or thienopyridines like clopidogrel) 2 Expected major surgery within 30 days (these patients will receive bare metal stents) 3 Expected loss for follow up 4 Enrollment in another stent study with different stents 5 Inability to implant Taxus or Xience-V stent(s)

Design outcomes

Primary

Measure	Time frame
The primary end point of the study is the composite end point of: all death, non fatal myocardial infarction, target vessel revascularization at 1 year.	—

Secondary

Measure	Time frame
The secondary end points of the study are: A) The combined endpoint of cardiac death, non fatal myocardial infarction, ischemic driven target lesion revascularization (TLR) rate at 1, 6 and 12 months follow-up. B) The combined endpoint of all death, non fatal myocardial infarction, target vessel revascularization (TVR) rate at 2, 3, 4 and 5 years.	—

Countries

Netherlands

Outcome results